These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 31783891)

  • 1. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper.
    Cholley B; Levy B; Fellahi JL; Longrois D; Amour J; Ouattara A; Mebazaa A
    Crit Care; 2019 Nov; 23(1):385. PubMed ID: 31783891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety.
    Heringlake M; Alvarez J; Bettex D; Bouchez S; Fruhwald S; Girardis M; Grossini E; Guarracino F; Herpain A; Toller W; Tritapepe L; Pollesello P
    Expert Rev Cardiovasc Ther; 2021 Apr; 19(4):325-335. PubMed ID: 33739204
    [No Abstract]   [Full Text] [Related]  

  • 3. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
    Schumann J; Henrich EC; Strobl H; Prondzinsky R; Weiche S; Thiele H; Werdan K; Frantz S; Unverzagt S
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009669. PubMed ID: 29376560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
    Huang X; Lei S; Zhu MF; Jiang RL; Huang LQ; Xia GL; Zhi YH
    J Zhejiang Univ Sci B; 2013 May; 14(5):400-15. PubMed ID: 23645177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan in veno-arterial extracorporeal membrane oxygenator supported patients: Impact on the success of weaning and survival.
    Alonso-Fernandez-Gatta M; Merchan-Gomez S; Gonzalez-Cebrian M; Diego-Nieto A; Alzola E; Toranzo-Nieto I; Barrio A; Martin-Herrero F; Sanchez PL
    Artif Organs; 2021 Jul; 45(7):717-725. PubMed ID: 33377185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease.
    Burkhardt BE; Rücker G; Stiller B
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009515. PubMed ID: 25806562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society.
    Tycińska A; Gierlotka M; Bugajski J; Deja M; Depukat R; Gruchała M; Grześk G; Kasprzak JD; Kubica J; Kucewicz-Czech E; Leszek P; Płonka J; Sobkowicz B; Straburzyńska-Migaj E; Wilk K; Zawiślak B; Zymliński R; Stępińska J
    Kardiol Pol; 2020 Aug; 78(7-8):825-834. PubMed ID: 32788567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
    Uhlig K; Efremov L; Tongers J; Frantz S; Mikolajczyk R; Sedding D; Schumann J
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD009669. PubMed ID: 33152122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery.
    Mehta RH; Leimberger JD; van Diepen S; Meza J; Wang A; Jankowich R; Harrison RW; Hay D; Fremes S; Duncan A; Soltesz EG; Luber J; Park S; Argenziano M; Murphy E; Marcel R; Kalavrouziotis D; Nagpal D; Bozinovski J; Toller W; Heringlake M; Goodman SG; Levy JH; Harrington RA; Anstrom KJ; Alexander JH;
    N Engl J Med; 2017 May; 376(21):2032-2042. PubMed ID: 28316276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials.
    Cui D; Liao Y; Li G; Chen Y
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):73-81. PubMed ID: 32462455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper.
    Farmakis D; Alvarez J; Gal TB; Brito D; Fedele F; Fonseca C; Gordon AC; Gotsman I; Grossini E; Guarracino F; Harjola VP; Hellman Y; Heunks L; Ivancan V; Karavidas A; Kivikko M; Lomivorotov V; Longrois D; Masip J; Metra M; Morelli A; Nikolaou M; Papp Z; Parkhomenko A; Poelzl G; Pollesello P; Ravn HB; Rex S; Riha H; Ricksten SE; Schwinger RHG; Vrtovec B; Yilmaz MB; Zielinska M; Parissis J
    Int J Cardiol; 2016 Nov; 222():303-312. PubMed ID: 27498374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial.
    Cholley B; Caruba T; Grosjean S; Amour J; Ouattara A; Villacorta J; Miguet B; Guinet P; Lévy F; Squara P; Aït Hamou N; Carillion A; Boyer J; Boughenou MF; Rosier S; Robin E; Radutoiu M; Durand M; Guidon C; Desebbe O; Charles-Nelson A; Menasché P; Rozec B; Girard C; Fellahi JL; Pirracchio R; Chatellier G;
    JAMA; 2017 Aug; 318(6):548-556. PubMed ID: 28787507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis.
    Guilherme E; Jacquet-Lagrèze M; Pozzi M; Achana F; Armoiry X; Fellahi JL
    Crit Care; 2020 Jul; 24(1):442. PubMed ID: 32677985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double-Blind Controlled Trial.
    Lannemyr L; Ricksten SE; Rundqvist B; Andersson B; Bartfay SE; Ljungman C; Dahlberg P; Bergh N; Hjalmarsson C; Gilljam T; Bollano E; Karason K
    J Am Heart Assoc; 2018 Aug; 7(16):e008455. PubMed ID: 30369310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.
    Hummel J; Rücker G; Stiller B
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011312. PubMed ID: 28770972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.
    Hummel J; Rücker G; Stiller B
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011312. PubMed ID: 28262914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Individualized use of levosimendan in cardiac surgery].
    Woehrle T; Mehringer L; Juchem G; Dashkevich A; Weis M; Schünemann M; Kilger E
    Anaesthesist; 2021 Mar; 70(3):204-212. PubMed ID: 33001236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.